
|Articles|January 4, 2016
KaloBios Files for Bankruptcy Following Shkreli Arrest
January 04, 2016.
Advertisement
Following the arrest on December 17 of former CEO Martin Shkreli, KaloBios Pharmaceuticals (South San Francisco, CA) filed for bankruptcy last week. According to Bloomberg Business, the company plans to use the bankruptcy to buy time to implement its restructuring plans. Shkreli, who took charge of KaloBios just a month ago, was arrested on fraud charges related to his position at his former company, Retrophin. KaloBios fired the controversial CEO shortly after his arrest. http://www.bloomberg.com/news/articles/2015-12-30/shkreli-s-former-biotech-company-kalobios-files-for-bankruptcy-iisup3fw
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
When Drug Pricing Becomes Trade Policy
5




